Table 1.
Participant Characteristics in Each Dementia Diagnostic Groupa
| Alzheimer Disease (n = 1359) | Frontotemporal Dementia (n = 288) | Vascular Dementia (n = 138) | Dementia With Lewy Bodies (n = 51) | Corticobasal Syndrome (n = 61) | Control (n = 1849) | |
|---|---|---|---|---|---|---|
| Age, mean (SD), y | 69.4 (9.3) | 65.9 (8.2)b | 74.5 (8.5)b | 69.1 (7.6) | 66.6 (7.5) | 68.1 (14.0) |
| Age, median (range), y | 69 (38–95) | 66 (41–85) | 75 (46–90) | 68 (55–87) | 68 (40–88) | 68 (40–88) |
| Age groups, No. (%), y | ||||||
| <55 | 58 (4.3) | 25 (8.7) | 2 (1.4) | 2 (3.3) | 209 (11.3) | |
| 55–59 | 164 (12.1) | 37 (12.8) | 4 (2.9) | 4 (7.8) | 6 (9.8) | 128 (6.9) |
| 60–64 | 201 (14.8) | 62 (21.5) | 12 (8.7) | 12 (23.5) | 16 (26.2) | 173 (9.4) |
| 65–69 | 249 (18.3) | 63 (21.9) | 20 (14.5) | 12 (23.5) | 11 (18.0) | 352 (19.0) |
| 70–74 | 259 (19.1) | 62 (21.5) | 25 (18.1) | 11 (21.6) | 20 (32.8) | 334 (18.1) |
| 75–79 | 212 (15.6) | 29 (10.1) | 32 (23.2) | 7 (13.7) | 5 (8.2) | 305 (16.5) |
| 80–84 | 147 (10.8) | 9 (3.1) | 27 (19.6) | 3 (5.9) | 193 (10.4) | |
| ≥85 | 69 (5.1) | 1 (0.3) | 16 (11.6) | 2 (3.9) | 1 (1.6) | 155 (8.4) |
| Men, No. (%) | 721 (53.1) | 148 (51.4) | 85 (61.6) | 19 (37.3) | 29 (47.5) | 756 (41.4) |
| Education, mean (SD), y | 13.8 (3.6) | 13.6 (3.5) | 10.1 (4.2)b | 13.7 (3.1) | 13.7 (3.6) | 15.1 (3.3) |
| MMSE score, mean (SD)c | 21.8 (4.7)b | 23.8 (5.5) | 19.4 (5.8)b | 22.9 (5.4) | 22.5 (6.3) | 29.1 (1.2) |
| Global CDR, mean (SD) d | 0.9 (0.4) | 0.8 (0.6) | 1.2 (0.7)b | 1.1 (0.7)b | 0.9 (0.6) | 0 |
| APOE ε4 carrier/noncarrier (% carrier)e | 593/377 (61.1)b | 48/160 (23.1) | 30/77 (28.0) | 16/18 (47.1)b | 17/34 (33.3) | 478/1091 (30.5) |
Abbreviations: APOE, apolipoprotein E; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.
a
Participant characteristics were compared between diagnostic groups using analysis of variance and Fisher exact tests, with post hoc Bonferroni tests for all possible pairs.
b
Pairwise comparisons were statistically significant for the group indicated.
c
Range: 0 to 30, lower scores indicate worse global cognition.
d
Range: 0 to 3, higher scores indicate more advanced disease severity.
e
APOE datamissing in 27.8%of dementia participants and 15.9%of control participants.